HERG1 channel agonists and cardiac arrhythmia

Curr Opin Pharmacol. 2014 Apr;15:22-7. doi: 10.1016/j.coph.2013.11.006. Epub 2013 Nov 27.

Abstract

Type 1 human ether-a-go-go-related gene (hERG1) potassium channels are a key determinant of normal repolarization of cardiac action potentials. Loss of function mutations in hERG1 channels cause inherited long QT syndrome and increased risk of cardiac arrhythmia and sudden death. Many common medications that block hERG1 channels as an unintended side effect also increase arrhythmic risk. Routine preclinical screening for hERG1 block led to the discovery of agonists that shorten action potential duration and QT interval. Agonists have the potential to be used as pharmacotherapy for long QT syndrome, but can also be proarrhythmic. Recent studies have elucidated multiple mechanisms of action for these compounds and the structural basis for their binding to the pore domain of the hERG1 channel.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Action Potentials / drug effects
  • Action Potentials / physiology
  • Arrhythmias, Cardiac / chemically induced
  • Arrhythmias, Cardiac / drug therapy
  • Arrhythmias, Cardiac / metabolism*
  • Ether-A-Go-Go Potassium Channels / agonists*
  • Humans
  • Ion Channel Gating / drug effects

Substances

  • Ether-A-Go-Go Potassium Channels
  • KCNH1 protein, human